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Abstract
Background: High-mobility group box-1 protein (HMGB1) is a nuclear protein that regulates gene expression
throughout the body. It can also become cytoplasmic and function as a neuromodulatory cytokine after tissue
damage or injury. The manner in which HMGB1 influences the peripheral nervous system following nerve injury is
unclear. The present study investigated the degree to which HMGB1 signaling contributes to the maintenance of
neuropathic pain behavior in the rodent.
Results: Redistribution of HMGB1 from the nucleus to the cytoplasm occurred in both sensory neurons derived
from a tibial nerve injured (TNI) rat and in a sensory neuron-like cell line following exposure to a depolarizing
stimulus. We also observe that exogenous administration of HMGB1 to acutely dissociated sensory neurons derived
from naïve or TNI rodents elicit increased excitability. Furthermore systemic injection of glycyrrhizin (50 mg/kg; i.p.),
a known inhibitor of HMGB1, reversed TNI-induced mechanical hyperalgesia at fourteen days and three months
following nerve injury.
Conclusions: We have identified that a persistent endogenous release of HMGB1 by sensory neurons may be a
potent, physiologically relevant modulator of neuronal excitability. More importantly, the use of the anti-
inflammatory compound and known inhibitor of HMGB1, glycyrrhizin, has the ability to diminish persistent pain
behavior in a model of peripheral neuropathy, presumably through its ability to neutralize the cyotkine. The
identification of HMGB1 as a potential therapeutic target may contribute to a better understanding of mechanisms
associated with chronic pain syndromes.
Background
High-mobility group box 1 protein (HMGB1; also
known as amphoterin) is an ‘alarmin’ or damage-
associated molecular patterns (DAMPs) molecule that
rapidly mobilizes and activates innate and adaptive host
immune defense mechanisms [1]. HMGB1 is a highly
conserved 215 amino-acid non-histone nucleosomal
regulatory protein that is important for DNA repair and
replication. Though HMGB1is typically associated with
chromatin, it can be quickly released into the cytoplasm
following injury. More importantly, the cytoplasmic
HMGB1 can also act as a cytokine when released by
macrophages following injury, inflammation, or disease
[2-4]. Recent studies have demonstrated that HMGB1
release is not limited to leukocytes but can also be
released from activated or injured neurons [5].
Release of HMGB1 by neurons in the central nervous
system (CNS) plays a crucial role as potential source of
an endogenous inflammatory mediator that can influence
adjacent neurons and glia [6]. Recent evidence also sug-
gests that HMGB1 signaling in cortical cells may contrib-
ute to lower membrane thresholds and mediate rapid
changes in neuronal excitability [5,7]. There is also the
suggestion that HMGB1 may contribute to the develop-
ment of neuropathic pain states [8]. For example, peri-
sciatic or intrathecal administration of HMGB1 produces
rapid thermal hyperalgesia and mechanical allodynia in
the rat [8,9]. In contrast, spinal nerve ligation-induced
mechanical allodynia, but not thermal hyperalgesia, can
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be partially reversed if animals are pre-treated with
intrathecal anti-HMGB1 antibody therapy [8]. Though
HMGB1 may contribute to the development of neuro-
pathic pain, the cellular source of HMGB1 that contri-
butes to ongoing chronic pain behavior and the
underlying role of HMGB1 in neuropathic pain are
unknown.
In the present investigation, we examined the degree to
which HMGB1 contributes to the peripheral sensitization
of sensory neurons in a rodent tibial nerve injury (TNI)
model of neuropathic pain. We observed that HMGB1
protein is upregulated in a number of sensory neurons
for an extended period of time. Though not vesicle
bound, release of HMGB1 from a neuronal cell line was
found to occur in response to activity. Exogenous admin-
istration of HMGB1 increased excitability in acutely dis-
sociated sensory neurons. Finally, we asked whether
treatment with glycyrrhizin (GL) a natural anti-inflam-
matory and antiviral triterpene that binds directly to
HMGB1 [10], could influence neuropathic pain behavior
in the rodent. It was found that GL effectively reverses
TNI-induced mechanical allodynia both at fourteen days
and three months following nerve injury.
Material and methods
Animals
Pathogen-free, adult female Sprague Dawley (SD) rats
(150 to 200 g; Harlan Laboratories, Madison, WI, USA)
were housed in temperature (23 ± 3°C) and light (12-
hour light:12-hour dark cycle; lights on at 07:00 hours)
controlled rooms with standard rodent chow and auto-
claved tap water available. Experiments were performed
during the light cycle. Animals were randomly assigned
to the treatment groups. All animal related experiments
were approved by the Institutional Animal Care and Use
Committee of Indiana University School of Medicine.
All procedures were conducted in accordance with the
Guide for Care and Use of Laboratory Animals pub-
lished by the National Institutes of Health and the eth-
ical guidelines of the International Association for the
Study of Pain.
Tibial nerve injury
All rodents will be anesthetized during the procedure
with isoflurane (4% induction, 2% maintenance). To
model neuropathic pain we performed a tibial nerve
injury (TNI) [11-13]. SD rats 150 to 200 g were
anesthetized using isoflurane at 4% induction and 2%
maintenance. Under anesthesia, the right sciatic nerve
was isolated under aseptic surgical conditions by blunt
dissection of the femoral biceps muscle, without dam-
aging the epimycium. The sciatic nerve and its three
branches were isolated: the sural, common peroneal
and tibial nerves and only the tibial nerve was tightly
ligated with 5–0 silk and transected distal to the
ligation. The removal of an additional 2 to 4 mm of dis-
tal nerve stump was removed to prevent re-innervation
by the proximal nerve. The overlying muscle and skin
was then sutured in two separate layers. Sham-injured
animals were subjected to all preceding procedures with
the exception of ligation and transection. Following sur-
gery, the animals were returned to the animal housing
facility.
Behavioral assessment
All rodents were habituated to testing chambers for at
least two days. Rodents were randomly assigned to sham
or injured test groups. All baseline testing occurred be-
fore and after TNI. The incidence of foot withdrawal in
response to mechanical indentation of the plantar sur-
face of each hindpaw was measured with a flat-tipped
cylindrical probe measuring 200 μm in diameter [14].
Von Frey filaments capable of exerting forces of 10, 20,
40, 60, 80 and 120 mN with a uniform tip diameter was
applied to a designated loci present on the plantar sur-
face of the foot. During each test, the rodent was placed
in a transparent plastic cage with a floor of wire with ap-
proximately 1 cm2 openings. The cage was elevated so
that stimulation was applied to each hind foot from be-
neath the rodent. The filaments were applied in order of
ascending force. Each filament was applied alternately to
each foot. The duration of each stimulus was approxi-
mately one second and the interstimulus interval was
approximately 10 to 15 seconds. The incidence of foot
withdrawal was expressed as a percentage of the six
applications of each stimulus and the percentage of
withdrawals was then plotted as a function of force. The
von Frey withdrawal threshold was defined as the
force that evoked a minimum detectable withdrawal
observed on 50% of the tests given at the same force
level. For cases in which none of the specific fila-
ments used evoked withdrawals on exactly 50% of the
tests, linear interpolation will be used to define the
threshold.
Pre-TNI baseline behavioral assessment was estab-
lished in all rodents. Upon completion of behavioral
testing, animals were euthanized and tissue was col-
lected for further analysis. For some experiments, ani-
mals were injected with glycyrrhizin (GL; Sigma Aldrich,
St. Louis, MO, USA). Glycyrrhizin was prepared in sa-
line solution on the day of the experiment (pH 7.5).
Sham-control animals and TNI-induced animals were
given intraperitoneal (i.p.) injections of GL (50 mg/kg)
or saline (vehicle). A higher dose of GL (100 mg/kg) did
not produce further enhanced paw withdrawal thresh-
olds (data not shown). Our dosing paradigm following
TNI was either a single injection of GL or a once daily
injection of GL for four days.
Feldman et al. Journal of Neuroinflammation 2012, 9:180 Page 2 of 11
http://www.jneuroinflammation.com/content/9/1/180
Immunocytochemistry and immunohistochemistry
F11 cells or primary sensory neuron cultures grown on cov-
erslips and after experimental treatments were fixed with
PBS/4% paraformaldehyde for 15 minutes. For immunohis-
tochemistry, animals were sacrificed and transcardially per-
fused with saline followed by 4% paraformaldehyde. Fixed
cells or fixed tissue was then embedded for sectioning and
processed using immunocytochemical and immunohisto-
chemical methodologies commonly used in this laboratory
[15]. Lumbar L4/L5 dorsal root ganglia (DRG) tissue were
serially sectioned at 14 μm and were used in immunohisto-
chemical experiments (n=3; for each treatment group).
Primary antisera used was the rabbit anti-HMGB1 antibody
(1:1,000; Sigma Aldrich), rabbit anti-ATF3 (1:1,000; Santa
Cruz Biotechnology, Inc., Santa Cruz, USA), Hoescht nu-
clear stain (1:1,000; Sigma Aldrich). Sections were incu-
bated in secondary donkey ant-Rabbit conjugated to CY3
(Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA, USA).
Western blot analysis
Animals were sacrificed and transcardially perfused
with saline and tissue was removed and frozen im-
mediately with liquid nitrogen and stored at −80°C.
The fresh frozen L4/L5 DRG tissue samples, ipsilat-
eral to the injury, were homogenized in radioimmu-
noprecipitation assay (RIPA) buffer with protease/
phosphatase inhibitors and protein concentration
was determined using the bicinchoninic acid BCA
protein assay (Thermo Fisher Scientific, Rockford,
IL, USA). Samples (40 μg/lane) were separated by
10% SDS-PAGE and transferred to a nitrocellulose
membrane. After incubation in 10% non-fat milk block-
ing solution overnight at 4°C, the membrane will be incu-
bated with rabbit anti-HMGB1 (1:1,000; Sigma Aldrich)
followed by incubation with horseradish peroxidase-
coupled anti-rabbit secondary antibody (Jackson Immu-
noResearch). The membrane was reprobed with a mono-
clonal anti β-actin antibody (1:5,000; Sigma Aldrich).
Immunopositive bands were detected by enhanced
chemiluminescence (ECL) and measured by a denso-
metric analysis (Unscanit, Silk Scientific Inc., Orem,
UT, USA).
Nuclear and cytoplasmic extraction
Nuclear and cytoplasmic extracts were prepared using
NE-PER Nuclear and Cytoplasmic Kits (Thermo Fisher
Scientific). Fresh L4/5 DRG tissue ipsilateral to the injury
were collected and stored at −80°C. Monoclonal lamin
B, nuclear protein, (1: 1,000; Santa Cruz Biotechnology)
and monoclonal α Tubulin, cytoplasmic protein (1:1,000;
Santa Cruz Biotechnology) were used as loading
controls.
F11 Cell line
F11 cells (a mouse N18TG2 neuroblastoma rat DRG
sensory neuron hybrid cell line) were grown as mono-
layers either in 100-mm plastic dishes under 5% CO2 in
Ham’s F-12 medium supplemented with 20% fetal bovine
serum (FBS; Hyclone Laboratories, Inc., Logan, UT,
USA), 100 pM hypoxanthine/1 pM aminopterin/l2 pA4
thymidine, and 50 IU/ml of penicillin/streptomycin.
Cells were differentiated preceding an experiment with
Ham’s F-12 medium supplemented with 1% fetal bovine
serum, 50 ng/ml of NGF, 2 pM retinoic acid, 0.5 mM
dibutyryl cyclic AMP, 10 pM3-isobutyl-1-methylxanthine
(IBMX), a 1:500 dilution of 2.5 mg/ml of bovine insulin,
a 1:100 dilution of 10 mg/ml of transferrin, and 50 IU/ml
of penicillin/streptomycin.
Extracellular HMGB1 release measurement
F11 neuronal cell line was differentiated for either 48
hours or 96 hours in a 24 well plate. F11 neuronal cells
were washed twice with a balanced sterile solution (BSS)
[NaCl (140 mM), Hepes (10 mM), CaCl2 (2 mM),
MgCl2(1 mM), glucose (10 mM), KCl (5 mM)]. To
stimulate the cells, high concentration of potassium so-
lution (50 mmol/L KCL, denoted as 50 K hereafter) was
prepared by adjusting concentration of KCl from 5 to
50, and NaCl from 145 to 100. 50 K, BSS, and ionomy-
cin (2 μM) was applied for one hour. Extracellular super-
natants were collected and briefly spun and samples
were concentrated using a centrifugal filter device (Ami-
con Ultra-4-10 K; Millipore Corp., Billerica, MA, USA).
Western blot analysis was performed to detect HMGB1
protein levels in extracellular supernatants.
Preparation of acutely dissociated dorsal root ganglion
neuron
The L4 to L6 DRGs, ipislateral to the injury, were acutely
dissociated using methods described by Ma and LaMotte
[16]. Briefly, L4 to L6 DRGs, ipsilateral to the injury, were
removed from sham or TNI animals at post-injury day
(PID) 7, 14, and 28. The DRGs were treated with collage-
nase A and collagenase D Hanks’ balanced salt solution
(HBSS) for 20 minutes (1 mg/ml; Roche Applied Science,
Indianapolis, IN, USA), followed by treatment with papain
(30 U/ml; Worthington Biochemical Corp., Lakewood, NJ,
USA) in HBSS containing 0.5 mM EDTA and cysteine at
35°C. The cells were then dissociated by mechanical tritur-
ation in culture media containing 1 mg/ml bovine serum
albumin and trypsin inhibitor (Worthington Biochemical).
The culture media was Ham’s F-12 mixture, DMEM, sup-
plemented with 10% fetal bovine serum, penicillin and
streptomycin (100 μg/ml and 100 U/ml) and N2 (Life
Technologies, Corp., Carlsbad, CA, USA). The cells were
then plated on coverslips coated with poly-L lysine and
laminin (BD Biosciences, Franklin Lakes, NJ, USA) and
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incubated for two to three hours before more culture
media was added to the wells. The cells were then allowed
to sit undisturbed for 12 to 15 hours to adhere at 37°C
(with 5% CO2).
Cell counts
Images were taken with an intensified CCD camera
(Photometrics CoolSnap HQ2) coupled to a Nikon
microscope (Nikon Eclipse Ti) using Nikon Elements
software (Nikon Instruments Inc., Melville, NY, USA).
Tissue sections were illuminated with a Lamda DG-4
175 W xenon lamp (Sutter Instruments, Novata, CA,
USA). Within Elements software the image of each sec-
tion was set to a maximum threshold between 8000 and
8500. Total cell counts for each section were then taken
using the grid function to aide in total cell count. Both
HMGB1 and ATF-3 immunopositive cell counts were
conducted using Image Pro Software (Media Cybernet-
ics, Inc., Bethesda, MD, USA). The following parameters
were used for cell counts: intensity range (40 to 255),
smoothness (20), measurement window size (10 μM-∞).
Fluorescent artifacts such as axons and cell debris were
unselected so that these were not used in cell counts.
HMGB1 and ATF-3 immunopositive cell counts were
taken from independent tissue section images and com-
bined to reach the total percentage of neurons per gan-
glia. The criteria for neuronal HMGB1 cytoplasmic
localization counts include: 1) presence of Hoescht nu-
clear label, and 2) complete cellular membrane mor-
phology, and size of cell (> 10 μm).
Ca2+ imaging
The dissociated DRG cells were loaded with fura-2 AM
(3 mM, Invitrogen Corp., Carlsbad, CA USA) for 25 min-
utes at room temperature in a balanced sterile salt solu-
tion (BSS) (NaCl (140 mM), Hepes (10 mM), CaCl2
(2 mM), MgCl2 (1 mM), glucose (10 mM), KCl (5 mM).
The cells were rinsed with the BSS and mounted onto a
chamber that was placed onto the inverted microscope.
Intracellular calcium was measured by digital video micro-
fluorometry with an intensified CCD camera coupled to a
microscope and MetaFluor software (Molecular Devices
Corp., Downington, PA USA). Cells were illuminated with
a 150 W xenon arc lamp, and the excitation wavelengths
of the fura-2 (340/380 nm) were selected by a filter chan-
ger. Sterile solution was applied to cells prior to HMGB1
application, any cells that responded to buffer alone were
not used in neuronal responsive counts. HMGB1
(0.65 μg/ml) was applied directly into the coverslip bath-
ing solution. HMGB1 was purchased from R&D Systems
(Minneapolis, MN, USA; <1.0 endotoxin per 1 g of the
protein by the LAL method), and was reconstituted in
sterile 0.1% BSA/PBS. HMGB1 has a 50% binding of bio-
tinlyated HMGB1 at 0.35 to1.4 μg/ml, 0.65 μg/ml of
HMGB1 was applied for calcium imaging. If no response
was seen within one minute, the HMGB1 was washed out.
After HMGB1 application, high potassium 50 K (50 mM)
and capsaicin (3 nM) were added. Calcium imaging traces
were analyzed by two independent analyzers and only
responses that were in agreement between two individuals
were used in the counts.
Electrophysiology
Sharp electrode intracellular recordings were obtained
from primary afferent neurons 12 to 18 h after dissoci-
ation. Coverslips were transferred to a recording cham-
ber that was mounted on the stage of an inverted
microscope (Nikon Eclipse Ti; Nikon Instruments, Inc.).
The chamber was perfused with a bath solution contain-
ing (mM): NaCl 120, KCl 3, CaCl2 1, MgCl2 1, Hepes
10, Glucose 10, adjusted to pH 7.4 and osmolarity
300 Osm. The recordings were obtained at room
temperature. Intracellular recording electrodes were fab-
ricated from borosilicate glass (World Precision Instru-
ments, Sarasota, FL, USA) and pulled on a Flaming/
Brown micropipette puller (P-98, Sutter Instruments).
Electrodes were filled with 1.0 M KCl (impedance:
40–80 MΩ) and positioned by a micromanipulator
(Newport Corp., Irvine, CA, USA). A −0.1 nA current in-
jection was used to bridge-balance the electrode resist-
ance. Prior to electrode impalement, the size of the soma
to be recorded was classified according to its diameter as
small (≤30 μm), medium (31 to 45 μm) and large
(≥45 μm). Electrophysiological recordings were per-
formed with continuous current-clamp in bridge mode
using an AxoClamp-2B amplifier, stored digitally via
Digidata 1322A interface, and analyzed offline with
pClamp 9 software (Axon Instruments, Inc., Union City,
CA, USA). A neuron was accepted for study only when it
exhibited a resting membrane potential (RMP) more
negative than −45 mV. For each neuron isolated for
study, a continuous recording was obtained for one
minute without the delivery of any external stimulus.
Neuronal excitability of small and medium diameter
dissociated DRG sensory neurons was measured by
injecting one second current pulses into the soma
every 30 seconds. Current was adjusted in order to
elicit one to two action potentials per current injection
under baseline conditions. Following 3 control current
injections, HMGB1 (0.65 μg/ml) was applied to the
coverslip and current injections continued every 30 sec-
onds. Neuronal excitability was measured as number of
action potentials elicited per current pulse before and
after addition of HMGB1.
Statistics
GraphPad Software (LaJolla, CA, USA) was used to deter-
mine the statistical significance. Results were expressed as
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mean±SEM. When only two groups were compared,
Student’s t-test was used. Multiple comparisons were eval-
uated by Bonferroni test after one-way ANOVA. *P< 0.05
was considered to be statistically significant.
Results
TNI induces cytoplasmic HMGB1 in many sensory neurons
HMGB1 is limited largely to the nuclei of non-neuronal
cells and sensory neurons in the naïve DRG. (Figure 1A,
A1) Following TNI, HMGB1 is observed in both the cyto-
plasm and nucleus of numerous sensory neurons in the
L5 DRG in addition to some non-neuronal cells at post-
injury day (PID) 14 (Figure 1B, B1). The number of pri-
mary afferent neurons that exhibit cytoplasmic HMGB1
increased significantly when compared to naïve and sham-
injured animals. The percentage of positive cytoplasmic
HMGB1-IR sensory neurons is increased after TNI at PID
14 compared to sham and naïve (Figure 1C; n = 3,
ANOVA, F = 17.36; Bonferroni multiple comparison test,
*P< 0.01).
The expression of activating transcription factor 3
(ATF3), a cellular marker of nerve injury was used to re-
veal the primary afferent fibers that are engaged by TNI
[17,18]. After TNI injury PID 14, ATF3 immunoreactiv-
ity is present in 31.3% of total L5 DRG neurons ipsilat-
eral to the injury (Figure 1E; n = 3). ATF3 expression was
present in heterogeneous population of sensory neurons.
Sham and naïve DRGs did not exhibit ATF3 immunor-
eactivity (Figure 1D; n = 3). The relatively low number of
ATF-3 immunopositive sensory neurons in the sensory
ganglia relative to the percentage of neurons exhibiting
cytoplasmic HMGB1 immunoreactivity following TNI
suggests that direct nerve injury is not necessary for
neuronal translocation of HMGB1.
To confirm that HMGB1indeed exhibits a subcellular
redistribution, nuclear and cytoplasmic extracts from
L4/5 DRGs ispilateral to the injury were collected from
sham-injured and TNI animals at PID 14. Immunoblots
of HMGB1 in the specific extracts revealed that there
was an increase in cytoplasmic HMGB1 protein expres-
sion compared to sham control (Figure 2A, n = 3,
Students t-test, *P <0.05) and a decrease in nuclear
HMGB1 protein expression compared to sham control
(Figure 2B, (n = 4, Students t-test, P< 0.01). However,
total HMGB1 protein content in the L4/5 DRG was not
altered by nerve injury (Figure 2C, naïve and sham n= 3
each; TNI (PID 14) (n = 6, ANOVA, F = 3.38; P> 0.05).
HMGB1 Release in F11 cells is activity-dependent
We used the F11 cell line as a surrogate sensory neuron
to determine whether HMGB1 could be released in a
time dependent manner following exposure to high K+ -
50 mM (50 K). F11 cells were differentiated with NGF
and dibutyryl cAMP (db-cAMP) for 48 hours prior to
Figure 1 Subcellular localization of high mobility box group 1 (HMGB1) in L5 dorsal root ganglion (L5DRG) primary afferent neurons
following tibial nerve injury (TNI) in rats. (A) Sections of L5DRG stained for HMGB1 immunoreactivity (−IR) are localized primarily to the nuclei
of both neuronal and non-neuronal cells (A1; arrows) in the naive L5DRG. (B) By post-injury day (PID) 14, HMGB1-IR is localized to the cytoplasm
of L5DRG neurons (B1; arrowheads). There are some nuclei of non-neuronal cells that also exhibit HMGB1-IR (B; arrows). (C) Cell counts performed
on sections of sensory ganglia derived from naïve, sham and TNI animals revealed that a large number of sensory neurons exhibit HMGB1 in the
cytoplasm (*P< 0.01). (D) Naïve sections of L5DRG stained for activating transcription factor 3 (ATF3)-IR. (E) By PID 14, ATF3-IR is localized to the
nucleus of L5DRG neurons (arrow). Scale bar 50 μm.
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stimulation (Figure 3B). Not unlike naïve DRG sensory
neurons, HMGB1 immunoreactivity (−IR) was present
in the nucleus and absent in the cytoplasm of F11 cells
(Figure 3C, C1). Following depolarization with 50 K for
one hour, HMGB1 accumulation was observed in the
cytoplasm of numerous F11 cells (Figure 3D, D1), in
addition to pronounced levels of HMGB1 in the extra-
cellular supernatant (Figure 3A). Blebbing of F11 cell
nuclei, an indicator of cell death, was not in evidence
following one h exposure to 50 K. Despite evidence
demonstrating that exposure to 50 K elicits the release
of HMGB1 from the nucleus of F11 cells, the combin-
ation of 50 K and GL (50 or 100 μm), a triterpenoid sap-
onin glycoside known to neutralize HMGB1, did not
affect HMGB1 nuclear translocation in F11 cells (data
not shown).
HMGB1 activates calcium mobilization in sensory neurons
Using calcium mobilization techniques, it is possible to
functionally characterize sensory neurons that respond
to acute administration of HMGB1. Following HMGB1
application, capsaicin (transient receptor potential cation
channel subfamily V member 1;TRPV1 agonist) and high
K+ (50 K) (activates voltage gated Ca2+ channels) were
added to further characterize the phenotype of the
imaged cells. A response to 50 K is indicative of a non-
nociceptive neuron, while a response to capsaicin and
50 K is characteristic of a nociceptive neuron. Numerous
Figure 2 Distribution of high mobility box group 1 (HMGB1) in dorsal root ganglion (DRG) tissue derived from tibial nerve injury (TNI)
rats. (A) HMGB1 levels in the cytoplasm of L4/5 DRGs sham and post injury day (PID) 14 TNI DRG ipsilateral to the injury are statistically different
(*P< 0.01). (B) HMGB1 levels in nucleus of sham L4/5 and DRG derived from PID14 TNI animals were statistically different (*P< 0.01). (C) Western
blot analysis of total HMGB1 protein contents in naïve, sham injured and TNI L4/5 ispilateral to the injury at [PID] 14, P> 0.05.
Figure 3 Extracellular release of high mobility group box 1
(HMGB1) from F11 neuronal cell line. (A) Western blot analysis of
extracellular supernatant of HMGB1 after a 1 hour exposure to 50 K,
ionomycin (20 μM) and a balanced sterile solution (BSS) of F11
differentiated cells. (B) Representative image of F11 differentiated cells.
(C, C1) HMGB1 is confined in the nucleus of F11 differentiated neuronal
cell line in the BSS control sample (arrows). (D, D1) HMGB1 protein
relocates into the cytoplasm following a 1 hour exposure (arrows). Scale
bar 50 μm.
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nociceptive neurons responded to HMGB1 while signifi-
cantly fewer non-nociceptive neurons exhibited HMGB1-
induced calcium mobilization (Table 1).
As an additional control experiment, we addressed the
feasibility of GL to effectively neutralize the direct effects
of HMGB1 on sensory neurons. Using the described cal-
cium mobilization paradigm, we bath applied acutely
dissociated sensory neurons with GL/HMGB1. Following
washout of GL/HMGB1, the cells were then exposed to
capsaicin. The experimental outcome of these experi-
ments suggested that most capsaicin-sensitive sensory
neurons (>90%) did not respond to HMGB1 in the pres-
ence of 200 or 400 μM GL.
HMGB1 increases the excitability of primary afferent
neurons
Increased excitability of peripheral sensory neurons is
thought to contribute to chronic pain states following
nerve injury [14]. To determine the degree to which
HMGB1 can induce an increase in sensory neuron excit-
ability, we examined neuronal response using sharp elec-
trodes in current clamp mode. Following repeated
current pulse combined with HMGB1 administration,
we observed a significant increase in the excitability of
some small to medium diameter sensory neurons when
compared to baseline levels in both naïve (14.3% cells re-
spond to HMGB1; 1.36 action potentials (APs) for con-
trol vs. 5.22 APs for HMGB1; n = 24; Figure 4B) and
TNI derived sensory neurons (37.5% cells respond; 1.20
APs for control vs. 7.33 APs for HMGB1; n = 24,
Figure 4C). Representative recording of the number of
action potentials elicited in the TNI group under control
conditions and in the presence of HMGB1 (Figure 4A)
and grouped data for naïve (Figure 4B) and TNI sensory
neurons (Figure 4C) demonstrate that the excitability of
these neurons was significantly increased by HMGB1
when compared with control levels with and without
TNI injury (*P< 0.05 for both naïve and TNI groups;
Student’s t-test).
Glycyrrhizin reduces pain hypersensitivity in the TNI
model of neuropathic pain
TNI produces a significant reduction in the paw with-
drawal threshold (PWT) to tactile stimulus which lasts
for several months (PID 3 to 64) [13]. To investigate the
degree to which HMGB1 modulates TNI-induced tactile
hyperalgesia, we utilized a treatment paradigm described
by Ohnishi and colleagues [19] that included either a
one-time injection of glycyrrhizin via an intraperitoneal
(i.p.) route, (50 mg/kg) at PID 7 or one injection per day
over four consecutive days, PID 11 to 14 (Figure 5A).
This same treatment paradigm was again repeated over
consecutive days, PID 61 to 64 (Figure 5A). Interestingly,
a single injection of glycyrrhizin produced only a partial
reduction in the PWT to tactile stimulus at PID 7 and
PID 56 (Figure 5B; n= 6 *P< 0.01, ANOVA, F = 19.1,
Bonferroni’s multiple comparison test). However, four
consecutive days of glycyrrhizin at either PID 11 to14 or
PID 61 to 64, produced PWTs that nearly returned to
pre-injury baseline levels. This behavior represented
strongly significant differences when compared to ve-
hicle controls (Figure 5B; n = 6, *P< 0.01, ANOVA,
F = 265.9; Bonferroni’s multiple comparison test).
Discussion
Previous studies have implicated HMGB1, a cytokine me-
diator of inflammation, as having a critical role in neuro-
pathic pain [8,20,21]. In the present investigation, we
found that HMGB1 undergoes a chronic subcellular
Table 1 Acute administration of HMGB1 (0.65 μg/ml)







HMGB1 70% (31/44) 19% (26/136)
Figure 4 HMGB1 increases the excitability of nociceptive dorsal root ganglia (DRG) neurons. Current clamp recordings were performed on
small-to-medium (>30 μm - >40 μm) diameter lumbar 4–5 DRG neurons from TNI and naive rats. Firing of 1–2 action potentials (APs) was
elicited by a 1 second depolarizing current injection (ranging from 0.1 to 2.0 nA depending on the cell) every 30 seconds. (A) Representative
recordings demonstrating that application of HMGB1(0.65 μg/ml) increases the number of elicited action potentials in TNI DRG sensory neurons.
Group data showing that HMGB1 caused a significant increase in DRG action potential firing under both naive (B) and TNI conditions, p< 0.05
versus control (C).
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redistribution from the nucleus to the cytoplasm of pri-
mary afferent neurons following peripheral nerve injury.
Given evidence that cytoplasmic HMGB1 can undergo
exocytosis in other cell types [4,22], we further determined
that activity can contribute to the release of cytoplasmic
HMGB1 from a sensory neuron cell line. We also
observed that HMGB1 administration to acutely disso-
ciated primary afferent neurons directly increases the ex-
citability of some sensory neurons. Finally we demonstrated
that systemic treatment paradigms using GL, a natural anti-
inflammatory triterpene that binds directly to HMGB1, can
partially reverse pain behavior at PID 7 and PID 56.
Though a single dose of GL can elicit a statistically signifi-
cant reversal of stimulus dependent pain behavior, a four
day treatment paradigm produces a near complete recovery
to pre-injury PWT baseline at PID 14 and PID 64 days. To-
gether these results suggest that HMGB1 has a significant
role in sensitizing primary afferent neurons and may dir-
ectly contribute to neuropathic pain behavior.
After cellular damage or injury, HMGB1 can be trans-
located from the nucleus to the cytoplasm and secreted
from a variety of cell types by passive and active secre-
tion including neurons [4,7,14,22-24]. Passive secretion
of HMGB1 is often a result of damage to the cells and
occurs instantaneously [25]. Active secretion occurs in
cells undergoing profound stress, for example, following
exposure to a number of inflammatory mediators includ-
ing TNFα, IL-1, and IFN-γ [3,26,27]. More recent stud-
ies in the nervous system demonstrate that when
glutamate-exposed primary cortical neurons undergo
excitotoxic cell death, these cells secrete HMGB1 [7].
Herein, we directly demonstrated in that following per-
ipheral nerve injury or exposure to a depolarizing event
elicits translocation of HMGB1 from the nucleus to the
cytoplasm in both sensory neurons and a sensory
neuron-like cell line. More importantly, a depolarizing
event in vitro can elicit neuronal release of HMGB1 into
the extracellular environment. Unlike cultured cortical
neurons treated with glutamate, this neuronal depo-
larization did not elicit sensory neuron cell death. Though
the mechanisms of HMGB1 release in neurons is largely
unknown, cytoplasmic HMGB1 may be further phosphory-
lated by the classical protein kinase C (cPKC) and secreted
by a calcium-dependent mechanism via calcium/calmodu-
lin-dependent kinases (CaMKs) [28,29].
That HMGB1 can be released by both injured and non-
injured sensory neurons suggests a possible influence on
nearby neurons, adjacent nerve fibers, and possibly non-
neuronal cells in the nervous system. Strong evidence sup-
porting such a signaling event by HMGB1 was discovered
by Maroso and colleagues in a chronic epilepsy model.
This group elegantly demonstrated that blockade of
HMGB1 markedly reduced seizure duration and fre-
quency in rodent cortical neurons [7]. Our results herein
parallel findings in cortical neurons in that exposure to
HMGB1 can elicit robust states of excitability in primary
afferent neurons. These data suggest that HMGB1 is likely
to play a modulatory role in ongoing states of peripheral
sensitization following nerve injury.
A number of studies have provided evidence of a role of
HMGB1 signaling in nervous system pathology following
injury within either the peripheral or central nervous
Figure 5 Pre-treatment of glycyrrhizin (GL) once daily for 4 days reduces tibial nerve injury (TNI) induced pain hypersensitivity. The
glycyrrhizin treatment paradigm includes a one-time injection of glycyrrhizin (i.p.; 50 mg/kg) or treatment with glycyrrhizin one injection per day
over four consecutive days (A). (B) A one-time injection of glycyrrhizin at TNI [PID] 7 or [PID] 56 produced only a partial effect on the paw
withdrawal threshold (PWT). Treatment with glycyrrhizin injections over four consecutive days [PID11-14] or [PID61-64] successfully reversed TNI
decreases in PWT (*p< 0.01).
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system [5,30]. Shibasaki and colleagues demonstrated that
injection of HMGB1 into the sciatic nerve produced
dose-dependent thermal and tactile hyperalgesia [8], while
direct administration of HMGB1 into the central nervous
system by the intrathecal route produced robust mechan-
ical hyperalgesia that lasted for up to two hours [9,31].
More importantly, multiple exposures to HMGB1 neutral-
izing antibodies partially reverse spinal nerve ligation-
induced mechanical hyperalgesia and bone cancer pain
[8,31]. Taken together, it appears that ongoing HMGB1 re-
lease after a nerve injury may be a critical factor for the
maintenance of neuropathic pain and may be due to a
feed-forward regulation state [32].
Like other proinflammatory mediators HMGB1 exhibits
both active (acetylation/phosphorylation) or passive re-
lease (18). The basis of these molecular mechanisms that
contribute to these release kinetics are largely unknown.
That GL is effective after repeated injections suggests that
the release of HMGB1 is an ongoing feed-forward mech-
anism [4]. Effectively speaking, the presence of extracellu-
lar HMGB1 serves to activate HMGB1 receptor activation
which may continue the expression, production and trans-
location of HMGB1. Since TNI contributes to both nu-
clear and cytoplasmic HMGB1, it is likely that HMGB1 is
undergoing transcription and translation. More import-
antly, we observed that total HMGB1 protein expression
did not change suggesting that production of HMGB1 is
ongoing after injury; otherwise a decrease in total protein
expression would be evident.
Oral GL is metabolized in the intestine to 18β-
glycyrrhetinic acid (GA) and intravenous (IV) glycyrrhizin
is metabolized into glycyrrhetinic acid when excreted
through the bile into the intestines [33]. Both GA and GL
are known to directly interact with HMGB1 and inhibit its
inflammatory actions in leukocyte chemotaxis, cancer,
and post-ischemic liver and brain [10,19,25,30,34,35].
Interestingly, only the metabolite GA is able to cross the
blood–brain barrier [36]. GA is produced by bacteria in
the intestine after oral administration of GL and exhibits a
bioavailability of only 1% in plasma [37]. However, GL bio-
availability following intraperitoneal administration is esti-
mated to be 65 to 90%. Given the manner in which we
administer the compound, it is unlikely that GL directly
impacts neural or non-neural cells in the spinal cord or
brain.
HMGB1 neuronal signaling in neuropathic pain may
be dependent on either of two receptors, receptor for
advanced glycation end products (RAGE) and/or Toll-
like receptor 4 (TLR4). It is known that functional
RAGE is present in sensory neurons [38]. Shibasaki and
colleagues have demonstrated that after spinal nerve
ligation RAGE expression was increased in the primary
afferent neurons, satellite glial cell in the DRG, and
Schwann cells in the spinal nerve [8]. Based on these
findings, this group theorized that HMGB1/RAGE sig-
naling might be a promising therapeutic strategy for the
management of neuropathic pain. However, the injury-
induced release of HMGB1 and its receptor interaction
is not restricted to the RAGE as TLR4 is another major
receptor of HMGB1 in neuropathic pain models [39].
The characterization of HMGB1/TLR4 interactions has
led to the discovery of a cysteine residue at position 106
within HMGB1, which directly binds to TLR4 and
induces cytokine release in macrophages [40]. This same
activation of TLR4 site is present on adult cortical neu-
rons and induces heightened excitability in the form of
seizure activity [7,41,42]. TLR4-dependent neuronal excit-
ability is not limited to the CNS as primary sensory neu-
rons exposed to the endotoxin lipopolysaccharide (LPS),
the prototypical agonist of TLR4, produces increased ex-
citability [43], concentration-dependent increase in cal-
cium, inward ion currents and the release of calcitonin
gene-related peptide (CGRP) [44]. Subsequently, there is
evidence for the central involvement of TLR4 function in
both spinal cord inflammation and pain behavior hyper-
sensitivity [31,39,45,46].
The subsequent cell signaling function initiated by
HMGB1 through its respective receptors may lead to a
cascade of metabolic responses [47] or the increased
production of pro-inflammatory mediators that sustain a
chronic inflammatory state [48]. Further investigation is
necessary to elucidate HMGB1 signaling through TLR4
and/or RAGE in the injured peripheral nervous system
(PNS) and may reveal novel mechanisms of neuronal
HMGB1 activation that contribute to ongoing peripheral
sensitization and neuronal hyperexcitability in chronic
pain states.
Conclusions
Our present study has definitively found that HMGB1 is
actively released and serves as a relevant ligand for the
maintenance of neuropathic pain. We have also discovered
that ongoing HMGB1 release within the peripheral ner-
vous system contributes to mechanical behavioral hyper-
algesia, such that multiple injections of GL (HMGB1
neutralizing agent) effectively attenuated injury-induced
mechanical hyperalgesia. Taken together, we believe that
HMGB1 can directly alter sensory neuron function and
that the ongoing release of HMGB1 in the periphery con-
tributes to neuropathic pain.
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